Abstract / Synopsis:
With the development of risuteganib, a treatment for dry AMD may be on the horizon.
This article was reviewed by David S. Boyer, MD
The development of risuteganib (Luminate, Allegro Ophthalmics) may help to fill a void that has been open for a long time. Though dry age-related macular degeneration (AMD) has no established treatment, this novel drug may change that.
“The pathogenesis of dry AMD is not well established. However, oxidative stress causes photoreceptor, and retinal pigment epithelial (RPE) degeneration incites inflammation—all of which lead to an eventual loss of function,” said David S. Boyer, MD, adjunct clinical professor of ophthalmology, University of Southern California Keck School of Medicine, Los Angeles.
Risuteganib—a small, synthetic, arginine-glycine-aspartate class peptide with a molecular weight of 0.75 kD and a retinal half-life of 21 days—is designed to regulate integrin functions, he explained.
A number of preclinical studies of the molecule have been conducted in the United States and Mexico have confirmed the drug’s anti-inflammatory component via the C3 receptor, reduced mitochondrial reactive oxygen species, and improved mitochondrial bioenergetics and cellular viability, according to Dr. Boyer.
The activity of risuteganib blocks oxidative stress in RPE cells and through that action ultimately eliminates photoreceptor and RPE degeneration and inflammation.
“Because of this, it is a natural to look at this drug for the treatment of dry AMD,” Dr. Boyer said.
Related: Focusing the battle against dry AMD
The safety and efficacy of 1.0 mg of risuteganib intravitreal injections was evaluated in a study population with intermediate non-exudative AMD.
The primary endpoint was the percentage of patients that gained eight or more letters of best-corrected visual acuity (BCVA) compared with sham treatment….